| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -30.1 | -7.5 |
| EPS (diluted, $ a share) | $-1.02 | $-0.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: NVCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nuvectis Pharma, Inc.: key numbers
- Share price
- $19.11Close, Nov 16
- Market cap
- $657M
- Shares outstanding
- 34.39MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nuvectis Pharma, Inc.
All →Nuvectis Pharma Financial Results
Nuvectis Pharma reported third quarter 2026 financial results and provided a corporate update following its transformational in-licensing of ex-China rights to NXP100 and NXP200. The company ended the quarter with approximately $140 million in cash, providing a projected runway into the second half of 2029. Management is currently in discussions with the FDA regarding the U.S. regulatory path for ciprocopan (NXP100) in PNH and expects to provide an update by year-end.
“The last few months have been truly transformational for Nuvectis. The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
“With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings.”
Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis